Shaping Tomorrow’s Oncology: Glenmark’s Entry into Immuno-Oncology Redefines Oncology Care in India

Glenmark Pharmaceuticals Ltd. has made its first foray into the world of immune-oncology in India on 24 June, 2025 by launching Tevimbra in India.

This marks a major step forward in the country’s fight against chronic conditions, such as metastatic non-small cell lung cancer (NSCLC) as well as esophageal squamous cell carcinoma (ESCC), and also presents as a major milestone in expanding the company’s innovative oncology portfolio.

The growing burden of NSCLC AND ESCC globally, in which NSCLC represents over 80% of all lung cancer cases combined, has accelerated the need for innovative therapeutic solutions, such as Tevimbra, that offers a promising option to improve treatment outcomes among the patients suffering from mentioned chronic conditions.

Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd, said “The sharp rise in cancer burden, has enhanced the demand for innovative solutions, so the access of TEVIMBRA to oncologists and patients will lead a meaningful impact. This major step by the Glenmark Pharmaceuticals Ltd in this area marks a significant step to build a world-class oncology portfolio that is innovative, inclusive, and at the same time presents better patient outcomes and also helps in changing their lives”.

TEVIMBRA: A Global Game-Changer in Oncology Immunotherapy, Now Powering Hope for Millions in India:

TEVIMBRA, also known as tiselizumab, is specifically designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1(PD-1) monoclonal antibody with high affinity and binding specificity against PD-1, which is designed to help the body’s immune cells to detect and fight tumours.

Due to these remarkable properities, TEVIMBRA, has been approved in 46 countries, and more than 1.5 million patients have been treated globally, which hence signifies its capacity towards treatment of cancer globally.

President and Business Head - India Formulations, Glenmark Pharmaceuticals Ltd, Alok Malik, said, “Glenmark is working towards transforming cancer care in India by making globally benchmarked immunotherapies more accessible, such as TEVIMBRA, a therapy with proven efficacy and better patient outcomes.”

Future of India’s Cancer Market: Advancing Immunotherapy Access, Innovation, and Industry Growth:

The monoclonal antibody sector is witnessing a significant growth, which is driven by the combined efforts of both public as well as private sectors. Various companies, such as Serum Institute of India, Gennova Biopharmaceuticals, and Sun Pharma, are consistently investing towards the development of monoclonal antibodies, while Glenmark’s entry with TEVIMBRA, further diversifies the oncology care treatment in India. Such developments, provide access of advanced globally recognized immunotherapies to oncologists, which further enhances innovation and improves patient outcomes.

Further, the entry of TEVIMBRA in the Indian market marks an important shift by making PD-1 therapies based monoclonal antibodies affordable, as compared to previously imported, high-cost alternatives, which thereby helps in improving the quality of cancer care in the hospitals across the country.

Moreover, the support from the Indian government, through the National Biopharma Mission, which was launched by the Department of Biotechnology (DBT), is working to establish India as a global hub for affordable novel monoclonal antibody development.

Such coordinated initiatives expanding access to advanced immunotherapies, that also help in strengthening India’s position in the global biopharmaceutical sector.